SGLT2 inhibitor-associated euglycemic ketoacidosis after percutaneous coronary intervention for ST-segment elevation myocardial infarction
Abstract
While sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular outcomes after myocardial infarction (MI), they carry the risk of euglycemic diabetic ketoacidosis (euDKA). We report the case of a 60-year-old male with type 2 diabetes mellitus who developed euDKA after a primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Despite exhibiting hemodynamic stability, the patient developed persistent metabolic acidosis. The diagnosis of SGLT2 inhibitor-associated euDKA was significantly delayed, as it was obscured by a combination of the patient's clinical stability, an initial normal anion gap acidosis from diarrhea, and the administration of sodium bicarbonate. This case highlights the fact that clinical stability after primary PCI might mask SGLT2 inhibitor-associated euDKA. This report also emphasizes that euDKA should be a critical diagnostic consideration in the face of persistent acidosis in STEMI patients treated with PCI and receiving SGLT2 inhibitors, even when they appear clinically stable.
Learning objectives: This case highlights that euglycemic diabetic ketoacidosis (euDKA) might be a critical and missed diagnosis in SGLT2 inhibitor-treated diabetic patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). SGLT2 inhibitor-associated euDKA should be considered in diabetic patients presenting with unexplained metabolic acidosis, even…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.